Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX Hider SL; Thomson W; Mack LF; Armstrong DJ; Shadforth M; Bruce INRheumatology (Oxford) 2008[Aug]; 47 (8): 1156-9OBJECTIVE: To examine the role of adenosine receptor 2a gene (ADORA2a) polymorphisms on outcome of MTX treatment in RA. METHODS: Subjects included 309 RA patients with a defined response to MTX. Patients were included if they were (i) good responders (n = 147) (ESR <20 for >6/12 on stable dose of MTX) (ii) inefficacy failures (n = 101) (physician statement and failure to reduce ESR/CRP by 20%) or (iii) adverse event (AE) failures (n = 61) (verified by medical record review). AEs were sub-divided into gastrointestinal (GI) (n = 24), abnormal LFTs (n = 20) or other (n = 17). 8 single nucleotide polymorphisms (SNPs) within ADORA2a were genotyped using the Sequenom MALDI-TOF platform. RESULTS: Five SNPs within ADORA2a were associated with stopping MTX for AEs (OR 2.1-3.07, P < 0.05 for all). Analysis by AE type showed that the association was specific for GI toxicity. No association was observed between ADORA2a and inefficacy outcomes. CONCLUSION: Genetic variation within ADORA2a is significantly associated with AEs on MTX, specifically GI AEs. Knowledge of the ADORA2a genotype may help to improve identification of patients at high risk of GI toxicity with MTX.|*Polymorphism, Single Nucleotide[MESH]|Adult[MESH]|Aged[MESH]|Antirheumatic Agents/*adverse effects/therapeutic use[MESH]|Arthritis, Rheumatoid/drug therapy/*genetics[MESH]|Gene Frequency[MESH]|Genetic Predisposition to Disease[MESH]|Humans[MESH]|Immunosuppressive Agents/adverse effects/therapeutic use[MESH]|Methotrexate/*adverse effects/therapeutic use[MESH]|Middle Aged[MESH]|Receptors, Adenosine A2/*genetics[MESH]|Retrospective Studies[MESH]|Treatment Outcome[MESH] |
